Nanomedicines: A Focus on Nanomaterials as Drug Delivery System with
                    Current Trends and Future Advancement

Pandey, Jaya; Dubey, Ravi Shanker; Kate, Aditya; Prasad, Bhim Bali; Sinha, Anurag; Mishra, Mohit

doi:10.1055/a-1824-4619

Cited by 4 publications

(2 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For drugs to be considered as TDDSs, they require five key characteristics: positioning (releasing the drug at the specified location), controlled release [13], non-toxicity, biocompatibility, and biodegradability [14]. The primary purpose of targeted drug administration is to improve drug efficacy and reduce the rate of adverse effects [15]. Improvements in dosing strategies also improve safety, effectiveness, reliability, and patient compliance; therefore, TDDSs are increasingly valued by the global medical community.…”

Section: Overview Of Targeted Drug Delivery Systemsmentioning

confidence: 99%

Research Progress of Drug Delivery Systems Targeting the Kidneys

Huang,

Ye,

Chen

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Chronic kidney disease (CKD) affects more than 10% of the global population, and its incidence is increasing, partially due to an increase in the prevalence of disease risk factors. Acute kidney injury (AKI) is an independent risk factor for CKD and end-stage renal disease (ESRD). The pathogenic mechanisms of CKD provide several potential targets for its treatment. However, due to off-target effects, conventional drugs for CKD typically require high doses to achieve adequate therapeutic effects, leading to long-term organ toxicity. Therefore, ideal treatments that completely cure the different types of kidney disease are rarely available. Several approaches for the drug targeting of the kidneys have been explored in drug delivery system research. Nanotechnology-based drug delivery systems have multiple merits, including good biocompatibility, suitable degradability, the ability to target lesion sites, and fewer non-specific systemic effects. In this review, the development, potential, and limitations of low-molecular-weight protein–lysozymes, polymer nanomaterials, and lipid-based nanocarriers as drug delivery platforms for treating AKI and CKD are summarized.

show abstract

Section: Overview Of Targeted Drug Delivery Systemsmentioning

confidence: 99%

Research Progress of Drug Delivery Systems Targeting the Kidneys

Huang,

Ye,

Chen

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…The rpoB mutations are more likely segregated in an 81-bp region called the rifampin resistance determining region (RRDR). With the advent of high-end computational power, MD simulations can be performed between μs to the ms time-scale that can accurately describe the dynamics of any system [24].…”

Section: Introductionmentioning

confidence: 99%

Molecular Docking Studies of Rifampicin – rpoB complex: Repurposing Drug Design Implications for against Plasmodium falciparum Malaria through a Computational Approach

Yadav

Pandey

2023

Drug Res (Stuttg)

Self Cite

View full text Add to dashboard Cite

Malaria is one of the world’s most devastating diseases, infecting well over 300 million people annually and killing between 2 and 3 million worldwide. Increasing parasite resistance to many existing drugs is exacerbating disease. Resistance to commonly used malarial drugs is increasing the need to develop new drugs urgently. Due to the slow pace and substantial costs of new drug development, repurposing of old drugs which is recently increasingly becoming an attractive proposition of highly efficient and effective way of drug discovery led us to study the drug rifampicin for this purpose. The present paper aims to investigate the route of Plasmodium falciparum apicoplast-targeted proteins that putatively encode β subunits of RNA polymerase with an objective to develop an effective antimalarial drug. Homology searching for conserved binding site to the rifampicin drug and the functional analysis of rpoB gene were done. Multiple Sequence alignment analysis of rpoB was compared with that in E.coli – rpoB and M. tuberculosis – rpoB. Docking studies of Rifampicin – rpoB complex was also done for finding binding affinity. The results of computational studies showed that rifampicin is a potential drug for malaria.

show abstract